ABIONYX PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.04 EUR | +1.96% |
|
-2.80% | -19.25% |
| Mar. 14 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
| Mar. 11 | Abionyx: reduced net loss in 2023 | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2023 | 4.6M 4.95M | Sales 2024 * | 4.6M 4.95M | Capitalization | 33.49M 36.07M |
|---|---|---|---|---|---|
| Net income 2023 | -3M -3.23M | Net income 2024 * | -6M -6.46M | EV / Sales 2023 | 9.02 x |
| Net cash position 2023 * | 100K 108K | Net cash position 2024 * | 3.4M 3.66M | EV / Sales 2024 * | 6.54 x |
| P/E ratio 2023 * |
-7.43
x | P/E ratio 2024 * |
-6.93
x | Employees | 63 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 68.01% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +1.96% | ||
| 1 week | -2.80% | ||
| Current month | -0.95% | ||
| 1 month | -5.80% | ||
| 3 months | -10.19% | ||
| 6 months | -11.11% | ||
| Current year | -19.25% |
1 week
1.01
1.08
1 month
0.991.13
Current year
0.911.32
1 year
0.912.16
3 years
0.903.57
5 years
0.203.57
10 years
0.2014.44
| Managers | Title | Age | Since |
|---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
| Director of Finance/CFO | - | 08-04-30 | |
Renee Benghozi
CTO | Chief Tech/Sci/R&D Officer | - | 15-02-08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Olivier Martinez
BRD | Director/Board Member | 54 | - |
Christian Chavy
BRD | Director/Board Member | 75 | 15-02-05 |
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.04 | +1.96% | 14,935 |
| 24-05-09 | 1.02 | -2.67% | 12,162 |
| 24-05-08 | 1.048 | -0.38% | 5,481 |
| 24-05-07 | 1.052 | -0.94% | 14,065 |
| 24-05-06 | 1.062 | -0.75% | 75,913 |
Real-time Euronext Paris, May 10, 2024 at 11:35 am EDT
More quotes
ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases.
At the end of 2023, the company boasted a portfolio of 3 products in clinical development.
Calendar
2024-05-15
- Q1 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.04
EUR
Average target price
10.5
EUR
Spread / Average Target
+909.62%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.25% | 36.07M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- ABNX Stock
